Osiris Therapeutics Inc - Strategic SWOT Analysis Review

  • ID: 4432331
  • SWOT Analysis
  • 35 pages
  • GlobalData
  • Osiris Therapeutics Inc
1 of 5

FEATURED COMPANIES

  • Athersys Inc
  • CymaBay Therapeutics Inc
  • Cytori Therapeutics Inc
  • Geron Corp
  • Microbot Medical Inc
  • MiMedx Group Inc
  • MORE
Osiris Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
Highlights

Osiris Therapeutics, Inc. (Osiris) is a regenerative medicine company involved in the research, development and marketing of regenerative medicine products. The company developed the world's first approved stem cell drug. It offers products in wound care, orthopedics, and sports medicine market. Osiris develops products based on BioSmart, a proprietary process for tissue and cell preservation that maintains integrity of the biological materials. Osiris, Grafix, Stravix and Cartiform are trademarks of Osiris. The company continues to advance its research and development (R&D) in biotechnology by focusing on innovation in regenerative medicine including stem cell research, bioengineering and viable tissue based products. Osiris is headquartered in Columbia, Maryland, the US.

Osiris Therapeutics Inc Key Recent Developments

Oct 23, 2017: Osiris Announces a Peer-Reviewed Publication of a Scientific Study Reporting Antimicrobial Properties of Human Cryopreserved Viable Amniotic Membrane
Oct 19, 2017: Osiris Therapeutics to Present 10 Advanced Clinical and Scientific Abstracts, Including an Exclusive Oral Presentation on its New Ambient Viable Tissue Preservation Technology
Jun 26, 2017: Osiris Appoints Linda Palczuk to serve as its President & CEO
Jun 26, 2017: Osiris Therapeutics appoints Linda Palczuk as president and CEO
May 31, 2017: Osiris Appoints David White to its Board of Directors

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with this detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Athersys Inc
  • CymaBay Therapeutics Inc
  • Cytori Therapeutics Inc
  • Geron Corp
  • Microbot Medical Inc
  • MiMedx Group Inc
  • MORE
Section 1 - About the Company
  • Osiris Therapeutics Inc - Key Facts
  • Osiris Therapeutics Inc - Key Employees
  • Osiris Therapeutics Inc - Key Employee Biographies
  • Osiris Therapeutics Inc - Major Products and Services
  • Osiris Therapeutics Inc - History
  • Osiris Therapeutics Inc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Osiris Therapeutics Inc - Business Description
  • Osiris Therapeutics Inc - Corporate Strategy
  • Osiris Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Osiris Therapeutics Inc - Strengths
  • Osiris Therapeutics Inc - Weaknesses
  • Osiris Therapeutics Inc - Opportunities
  • Osiris Therapeutics Inc - Threats
  • Osiris Therapeutics Inc - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Osiris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Osiris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • Osiris Therapeutics Inc, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Oct 23, 2017: Osiris Announces a Peer-Reviewed Publication of a Scientific Study Reporting Antimicrobial Properties of Human Cryopreserved Viable Amniotic Membrane
  • Oct 19, 2017: Osiris Therapeutics to Present 10 Advanced Clinical and Scientific Abstracts, Including an Exclusive Oral Presentation on its New Ambient Viable Tissue Preservation Technology
  • Jun 26, 2017: Osiris Appoints Linda Palczuk to serve as its President & CEO
  • May 31, 2017: Osiris Appoints David White to its Board of Directors
  • Apr 13, 2017: Osiris Announces Scientific Manuscript Comparing Impact of Preservation Methods on Tissue Integrity and Functionality is Available Electronically in Peer-Reviewed Journal
  • Apr 13, 2017: Osiris Announces Scientific Manuscript Comparing Impact of Preservation Methods on Tissue Integrity and Functionality is Available Electronically in Peer-Reviewed Journal
  • Apr 04, 2017: Osiris Therapeutics to Present 29 Advanced Clinical and Scientific Abstracts, Including a Late-Breaking Abstract on its New Ambient Viable Tissue Preservation Technology
  • Mar 31, 2017: Osiris Therapeutics Announces Change in its Board of Directors
  • Mar 30, 2017: Osiris Therapeutics Launches Prestige Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
  • Mar 27, 2017: Osiris Therapeutics Completes Restatement of 2014 Financial Statements
Section 5 - Appendix
  • Methodology
  • About
  • Contact
  • Disclaimer
List of Tables
  • Osiris Therapeutics Inc, Key Facts
  • Osiris Therapeutics Inc, Key Employees
  • Osiris Therapeutics Inc, Key Employee Biographies
  • Osiris Therapeutics Inc, Major Products and Services
  • Osiris Therapeutics Inc, History
  • Osiris Therapeutics Inc, Key Competitors
  • Osiris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Osiris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • Osiris Therapeutics Inc, Recent Deals Summary
List of Figures
  • Osiris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • Osiris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Vericel Corp
  • Symic Biomedical Inc
  • MultiCell Technologies Inc
  • MiMedx Group Inc
  • Microbot Medical Inc
  • Geron Corp
  • Cytori Therapeutics Inc
  • CymaBay Therapeutics Inc
  • Cellerant Therapeutics Inc
  • Athersys Inc
  • Astellas Institute for Regenerative Medicine
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll